| Oncologie. Conjugués anticorps-médicaments : une avancée pleine de défis | Revue médicale suisse |  | | 2025 | 52 | 0 |
|
| Decision-making at Swissmedic, the Swiss regulatory agency, with a focus on (neo)adjuvant cancer treatments | Oncology |  | | 2024 | 80 | 178 |
|
| Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022 : a comparative analysis | Lancet oncology | | | 2024 | 48 | 0 |
|
| Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient | Cancer biology & therapy | | | 2023 | 112 | 154 |
|
| A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration | Clinical and translational science | | | 2023 | 81 | 40 |
|
